36
Participants
Start Date
September 25, 2017
Primary Completion Date
February 19, 2020
Study Completion Date
March 31, 2035
TBI-1401(HF10)
1x10\^6 or 1x10\^7 TCID50/mL TBI-1401(HF10) administered by intratumoral injection at 2-week intervals. Patients may continue to receive the injections for up to 1 year if eligible for injection.
Gemcitabine
1000 mg/m\^2 Gemcitabine administered by intravenous infusion at weekly for 3 weeks followed by a week of rest.
Nab-paclitaxel
125 mg/m\^2 Nab-paclitaxel administered by intravenous infusion at weekly for 3 weeks followed by a week of rest.
TS-1
TS-1 (40-60 mg per body surface area) administered by oral at twice daily for 4 weeks followed by 2 weeks of rest.
Clinical Site, Nagoya
Clinical Site, Chiba
Clinical Site, Kashiwa
Clinical Site, Yokohama
Clinical Site, Osaka
Clinical Site, Chūōku
Clinical Site, Koto-Ku
Clinical Site, Nagoya
Takara Bio Inc.
INDUSTRY